OIG: Jury still out on impacts of vertical consolidation in Part D

By Paige Minemyer – A new analysis from the Office of Inspector General found a similar net cost for drugs through vertically-integrated Part D plans compared to other plans. Vertically-integrated firms accounted for 35% of contracts Part D in 2023, according to OIG's report. Eleven of the 300 organizations offering Part D coverage that year were considered vertically integrated, meaning they also owned a pharmacy benefit manager. Read Full Article...

HVBA Article Summary

1. Vertical Integration Changes Payment Structure in Part D: The report found that vertically integrated Medicare Part D organizations achieved similar net drug costs as other plans through different payment methods. These firms generally paid pharmacies more upfront but later recovered larger amounts through fees and rebates, while non-integrated plans typically paid less initially and collected fewer adjustments afterward. The analysis also found that integrated firms often paid their own pharmacies less, although incomplete pharmacy payment data limited the ability to fully evaluate the long-term financial impact.

2. Enrollees in Integrated Plans Face Different Cost Tradeoffs: According to the report, 79% of the 54.6 million individuals enrolled in Part D coverage were in plans operated by vertically integrated firms. These enrollees generally experienced lower monthly premiums but higher out-of-pocket prescription drug costs compared to members in other plans. The findings suggest that vertically integrated models may shift how costs are distributed between premiums and direct medication spending for consumers.

3. Market Concentration and Transparency Remain Key Concerns: The Office of Inspector General (OIG) said the overall impact of vertical integration in Part D remains difficult to measure due to limited transparency in pharmacy payment data and ongoing market changes. The report noted that recent policy and PBM transparency reforms could improve future evaluations of these payment models. OIG’s analysis also showed that six major national insurers accounted for 82% of gross Part D spending in 2023, led by UnitedHealth Group, CVS Health, and Humana.

UnitedHealthcare and Aetna have much different prior authorization programs

By Allison Bell – Academic researchers have looked at how commercial health insurers handle advance reviews of proposed treatment plans and winced. Aya Zaari Jabri, a management science specialist at Stanford, and colleagues analyzed 2024 commercial plan provider directories from Humana, CVS Health's Aetna subsidiary and UnitedHealth's UnitedHealthcare subsidiary. The researchers found each insurer had a completely different strategy for conducting prior authorization reviews. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Prior Authorization Requirements Vary Widely Among Insurers: Researchers found significant differences in how major insurers apply prior authorization reviews for employer-sponsored health plans. UnitedHealthcare reviewed 2,247 medical and surgical services at least some of the time, while Aetna reviewed only 573 services, and just 638 procedures were reviewed by all three insurers studied. The findings suggest there is little consistency across insurers regarding which procedures require additional approval before care is provided.

2. Employers Face Competing Concerns Around Prior Authorization: Physicians continue to criticize prior authorization processes for creating administrative burdens and potentially delaying patient care. At the same time, employers and benefits advisors may worry that eliminating prior authorization entirely could increase healthcare spending and employer plan premiums. Milliman analysts estimated that removing prior authorization reviews could raise premiums by approximately 3.3% to 4.8%, depending on how extensive the existing review program is.

3. Researchers Question Whether Current Reform Efforts Will Reduce Fragmentation: CMS recently encouraged major insurers to participate in a voluntary initiative aimed at streamlining and improving prior authorization processes. While insurers have pledged to reduce the number of reviewed services and adopt more electronic review systems, researchers noted there is still no plan for standardized processes across insurers. Physician skepticism also remains high, with only 33% of doctors surveyed by the American Medical Association believing the CMS effort would make a meaningful difference.

The Bill That Never Ends

By Wendell Potter – Jeni Rae Peters was a single mother and mental health counselor in Rapid City, South Dakota, when she was diagnosed with stage 2 breast cancer in 2020. She had health insurance through her employer. She kept working through surgery and chemotherapy because she knew that losing her job meant losing her coverage, and losing her coverage meant losing everything. As KFF Health News reported in its landmark “Diagnosis: Debt” investigation, the bills came anyway. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. High-Deductible Health Plans and Recurring Debt: Many Americans with serious illnesses, even those with health insurance, face significant financial burdens due to high-deductible health plans. Deductibles and out-of-pocket maximums reset annually, meaning patients with chronic or long-term conditions often accumulate new medical debt each year. This cycle can lead to persistent financial instability, regardless of continuous insurance coverage.

2. Financial Toxicity and Its Consequences: The article highlights that medical debt has far-reaching effects beyond immediate financial strain. Cancer patients with medical debt frequently experience damaged credit, harassment from debt collectors, and in some cases, bankruptcy or loss of housing. Research also indicates that those who go bankrupt due to medical bills have worse health outcomes, demonstrating that financial toxicity can directly impact patient survival.

3. Cost-Sharing Models Shift Risk to Patients: Over the past two decades, insurance companies and employers have increasingly shifted healthcare costs onto patients through mechanisms like deductibles, copayments, and coinsurance. While these measures were intended to reduce unnecessary care, in practice they often penalize the sick by making essential treatments financially burdensome. The system benefits insurers by reducing their claim payouts, but leaves patients vulnerable to ongoing debt and hardship.

Board votes to cap how much state, local governments spend on Ozempic

By Danielle J. Brown – State officials determined that Ozempic, a popular diabetes treatment and weight-loss drug, is unaffordable for Marylanders and voted Monday to limit how much state and local governments will pay for it on state health plans. Advocates say the Maryland Prescription Drug Affordability Board’s proposed “upper payment limit” on Ozempic, the name brand for semaglutide, could save state and local governments around $5.8 million a year on state health plans. The board’s decision comes a month after it voted to place an upper payment limit on another Type 2 diabetes drug, Jardiance, that could save the state around $320,000 a year. Read Full Article...

HVBA Article Summary

1. Maryland Drug Payment Limits Advance After Delays: The Maryland Prescription Drug Affordability Board approved preliminary upper payment limits for Ozempic and Jardiance following years of delays tied to funding, rulemaking, and implementation challenges. The proposals are still subject to a 30-day public comment period and require final approval before taking effect. If finalized, the payment limits would begin on Jan. 1, 2027, marking the state’s first use of direct prescription drug cost controls.

2. Debate Continues Over Savings and Patient Access: Supporters of the board’s action argue the payment limits could generate significant savings for state health plans and potentially reduce broader healthcare costs if expanded to private insurance markets. Critics, including patient advocacy groups and pharmaceutical industry representatives, warn the policy could lead to insurance restrictions such as formulary changes, adverse tiering, and expanded utilization management. They also expressed concern that lower drug pricing may not necessarily translate into reduced out-of-pocket expenses for patients.

3. Board Explores Additional Cost Strategies Amid Leadership Transition: In addition to the payment limits, the board voted to explore alternative cost-reduction approaches for GLP-1 medications, including a subscription-style payment model that would provide expanded access in exchange for a fixed annual fee. Estimates commissioned by Maryland Health Care for All project substantially larger savings if the board’s authority later expands beyond state health plans to all Maryland insurance markets. The developments come as Board Chair Van T. Mitchell announced plans to step down after leading the organization since 2020 through its lengthy launch and implementation process.

New Virginia law caps out-of-pocket insulin costs at $35

By Alan Goforth – Virginia Gov. Abigail Spanberger this week signed into law several bills that she said will address health care costs, make prescription drugs more affordable and ensure that more residents have access to the care they need. "Everywhere I go, people talk to me about the high cost of health care, both at the doctor's office and the pharmacy counter," she said. "That's why I made affordability the cornerstone of my legislative agenda and why we're taking decisive action to make health care more affordable for Virginia families." A bipartisan bill caps the out-of-pocket cost of a 30-day supply of insulin. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Insulin Cost Cap for Virginians: The new law sets a $35 monthly cap on out-of-pocket costs for a 30-day supply of insulin, aiming to make this essential medication more affordable for the estimated 800,000 Virginians living with diabetes. By limiting these expenses, the legislation seeks to reduce the financial burden on individuals who rely on insulin for their health. This move is part of a broader effort to address the high cost of prescription drugs in the state.

2. Broader Health Care Reforms Enacted: In addition to the insulin cap, Governor Spanberger signed several other bills targeting health care affordability and access. These include measures to reduce delays in patient care by cracking down on prior authorizations and expanding essential health benefits to cover services like doula care, infertility treatment, and hearing aids. The reforms also encourage providers to offer more affordable care by limiting certain insurance claim practices.

3. Bipartisan Support and Ongoing Efforts: The legislation received bipartisan backing, with all related bills passing the Virginia General Assembly with support from both parties. Recent actions by the governor also include efforts to regulate pharmacy benefit managers and expand health coverage for mothers and families at higher risk. These initiatives reflect a continued focus on making health care more accessible and affordable for all Virginians.

AI tools bring transparency to benefits

By Bruce Shutan – Advances in artificial intelligence are pulling back the curtain on benefits opacity, as seen in some of the latest point solutions being recommended in an increasingly crowded market. By promoting price transparency and a better overall employee experience, AI enables brokers and advisers to be more thoughtful stewards of the plans they suggest to employer clients. One such example is Collective Health, a third-party administrator whose concierge benefits navigation system helps health plan members better understand their coverage. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. AI Enhances Benefits Transparency: Artificial intelligence is increasingly being used to clarify complex employee benefits, making it easier for both employers and employees to understand coverage details and costs. By leveraging AI, brokers and advisers can provide more transparent and tailored plan recommendations. This shift helps reduce confusion and increases trust in the benefits process.

2. Accelerated and Informed Decision-Making: AI-driven platforms like those from Collective Health and Angle Health enable rapid generation of underwritten quotes and real-time analysis of claims data. This allows brokers and employers, especially those serving small and midsize businesses, to make quicker and more informed decisions about plan design and renewals. The ability to customize plans and contextualize premiums empowers organizations to manage their benefits more strategically.

3. AI Drives Action Beyond Error Detection: Companies such as Reclaim Health are using AI not just to identify billing errors but also to recover overpayments and optimize claims management. AI tools analyze self-insured claims data to detect patterns like duplicate billing or upcoding, and then advocate for financial recovery on behalf of employers and employees. This proactive approach is increasingly important as employers seek demonstrable returns on their benefits investments, rather than relying solely on detection methodologies.

Supreme Court turns away challenges to drug price talks

By Maya Goldman – The drug industry struck out at the Supreme Court on Monday in its ongoing efforts to scuttle Medicare drug price negotiations. Why it matters: It's the latest rebuff to industry arguments that the talks with the government violate free speech protections and due process rights, among other complaints. The negotiated prices that took effect this year are expected to generate $1.5 billion in savings to patients and $6 billion to Medicare. State of play: Justices, without comment, declined to take up petitions from six drugmakers. Read Full Article...

HVBA Article Summary

1. Supreme Court Declines to Hear Industry Challenges: The Supreme Court chose not to review petitions from six major pharmaceutical companies challenging the legality of Medicare drug price negotiations. This decision leaves in place lower court rulings that have consistently rejected the industry's arguments. The companies had claimed the process violated constitutional rights, but the high court's refusal to intervene is a setback for their efforts.

2. Significant Financial Impact for Medicare and Patients: The negotiated drug prices, implemented under the Inflation Reduction Act, are projected to save Medicare $6 billion and patients $1.5 billion in the current year. These savings are a direct result of the government's ability to negotiate prices for certain high-cost medications. The financial implications highlight the scale of the policy and its potential effect on healthcare spending.

3. Ongoing Legal Disputes Remain in Lower Courts: While the Supreme Court declined to hear these specific cases, other lawsuits challenging the drug price negotiation program are still active in lower courts. The pharmaceutical industry's main trade group, PhRMA, continues to argue that the program is unconstitutional. As a result, the issue could return to the Supreme Court in the future depending on the outcomes of ongoing litigation.

Workers feel financial stress at work, cut back on benefits

By Jimmy Nesbitt – More than half of U.S. employees say that financial stress is affecting their work, and many are scaling back contributions to workplace benefits, according to a new Morgan Stanley report. The company's sixth annual State of the Workplace Financial Benefits study comes amid heightened recession concerns and rising energy prices driven by the conflict in Iran. Eighty percent of HR managers say employees' financial issues hurt productivity, and 53% say financial stress-reducing benefits matter most for job satisfaction, ahead of mental or emotional support (26%) and physical wellness benefits (19%). Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Financial Stress Impacts Employee Behavior and Workplace Performance: A majority of employees report that financial stress is negatively affecting their work, while many are reducing contributions to workplace benefits such as 401(k)s and savings accounts. Economic concerns including inflation and uncertainty in the job market appear to be driving these decisions. Employees also identified budgeting, financial goal setting, and retirement planning as their most common financial challenges.

2. Workplace Financial Benefits Influence Employee Retention and Engagement: The survey found that employees increasingly value employers that provide personalized financial support and planning resources. Many employees said they would feel more invested in their company if tailored financial benefits were offered, and a significant number would consider switching jobs for better financial support. Employers are also prioritizing hiring and retention strategies more heavily as workforce expectations continue to evolve.

3. Equity Compensation and Financial Education Are Seen as Key Motivators: Employees and HR leaders identified equity compensation as an effective tool for motivation and long-term engagement. Employees primarily view equity compensation as a way to support retirement and future financial goals, while HR leaders see it as a means of connecting employees to company success. The findings suggest companies that combine financial education, planning support, and comprehensive benefits may be better positioned to attract and retain talent.